Acute hepatitis C infection lowers serum lipid levels

K E Corey1, J Mendez-Navarro, L L Barlow

  • 1Gastrointestinal Unit, Massachusetts General Hospital, Boston, MA 02114, USA.

Insights

Acute hepatitis C infection causes temporary low cholesterol and LDL levels. Following viral clearance, lipid levels rebound, potentially exceeding pre-infection levels and increasing coronary heart disease risk.

Area of Science:

  • Hepatology and Virology
  • Cardiovascular Disease Risk Factors
  • Lipid Metabolism

Background:

  • Chronic hepatitis C is linked to lipid abnormalities and coronary heart disease risk.
  • The effect of acute hepatitis C infection on lipid profiles is not well understood.

Purpose of the Study:

  • To investigate the impact of acute hepatitis C virus infection and its clearance on lipid levels.
  • To assess potential long-term cardiovascular risks associated with these lipid changes.

Main Methods:

  • Retrospective analysis of lipid profiles in 38 patients with acute hepatitis C.
  • Comparison of lipid levels (cholesterol, LDL, non-HDL) before, during, and after acute infection.
  • Analysis of lipid changes in patients who achieved viral clearance versus those who developed chronic infection.

Main Results:

  • Acute hepatitis C infection significantly decreased cholesterol, LDL, and non-HDL cholesterol levels.
  • Viral clearance led to a significant increase in these lipid levels, often above pre-infection values.
  • No significant lipid level changes were observed in patients who developed chronic hepatitis C.

Conclusions:

  • Acute hepatitis C infection induces transient hypolipidaemia.
  • Post-infection lipid levels can exceed baseline, suggesting a potential increased risk for coronary heart disease.
  • Monitoring lipid profiles after acute hepatitis C resolution is recommended.

Related Concept Videos

Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Blood Studies for Cardiovascular System III: Serum Lipid Profile01:25

Blood Studies for Cardiovascular System III: Serum Lipid Profile

Understanding serum lipids is crucial for maintaining cardiovascular health and preventing heart disease and stroke.
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...